Should You Buy Hims & Hers Health Inc (HIMS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
Hims & Hers Health Inc. is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance shows revenue growth but significant declines in net income and EPS. Technical indicators are bearish, and analysts have expressed concerns about the company's future growth and competitive pressures in the weight-loss drug market. While hedge funds are buying, there are no strong proprietary trading signals or significant positive catalysts to justify immediate investment.
Technical Analysis
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 44.798, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 29.947, with resistance at 31.421 and support at 28.473. Overall, technical indicators suggest a bearish trend.
Analyst Ratings and Price Target Trends
Analyst sentiment is mixed to negative. BofA and Citi maintain Underperform and Sell ratings, citing concerns about 2026 revenue and EBITDA margin expectations, as well as competitive pressures. Barclays initiated coverage with an Overweight rating and a $48 price target, citing long-term growth potential. However, recent analyst updates suggest downside risks in the near term.
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29 USD and a high forecast of 85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29 USD and a high forecast of 85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 28.670
Current: 28.670
